Company profile: Ampersand Biomedicines
1.1 - Company Overview
Company description
- Provider of programmable medicines and platforms that precisely target disease sites, including AND-Body Therapeutics for disease-specific precision and modification; the AND-Platform, a computational and experimental system enabled by a proprietary Address Map; the Opportunity Atlas for identifying localized targets; and enhanced biologic generation via AbCheck’s antibody discovery technologies.
Products and services
- AND-Platform: A proprietary computational and experimental platform that engineers precisely targeted medicines using an Address Map to identify optimal localizer targets for site-specific activity
- AND-Body Therapeutics: Programmable medicines that act exclusively at disease sites, uniting disease-specific precision with disease modification to produce targeted therapeutic activity only where pathology is localized
- Opportunity Atlas: A systematic approach that identifies localized targets across a broad range of diseases, supporting the design of site-specific therapeutics by pinpointing disease-localized targets for precise, site-directed therapeutic design
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ampersand Biomedicines
Tahoe Bio
HQ: United States
Website
- Description: Provider of AI-powered tools that simulate human cell responses to guide drug discovery, including Mosaic for generating large-scale single-cell datasets and high-resolution in vivo phenotypic and transcriptomic profiling, single-cell RNA pooling to analyze drug action across diverse patients, and in vivo drug-cell interaction studies; initial applications in oncology; open-sources the Tahoe-100M dataset.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tahoe Bio company profile →
Albert Labs
HQ: Canada
Website
- Description: Provider of pharmaceutical drug development services focused on mental health, pursuing regulatory approval for active compounds. Offerings include KRN-101, a natural psilocybin medicine for cancer-related anxiety; psychedelic-assisted therapy training for mental health professionals; and real-world evidence studies to accelerate development and access of mental health medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Albert Labs company profile →
AiCure
HQ: United States
Website
- Description: Provider of AI-driven data analytics to understand patient response to treatments, offering a regulatory-compliant platform to capture and analyze digital biomarkers for predicting participant behavior and treatment response, a Patient Connect mobile app with computer vision for real-time dosing guidance and adherence, site services supporting clinical operations and engagement, and OpenDBM for open-source access to digital biomarker algorithms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AiCure company profile →
DSG
HQ: United States
Website
- Description: Provider of information technology services focused on data management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DSG company profile →
TraceLink
HQ: United States
Website
- Description: Provider of a SaaS network creation platform that connects people, companies, systems, and processes to build integrated business ecosystems with multienterprise applications, enabling digitalization, customer-centric agility and resiliency across end-to-end supply networks and leveraging the collective intelligence of entire industries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TraceLink company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ampersand Biomedicines
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ampersand Biomedicines
2.2 - Growth funds investing in similar companies to Ampersand Biomedicines
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ampersand Biomedicines
4.2 - Public trading comparable groups for Ampersand Biomedicines
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →